<p>Caribou Biosciences, Inc.（纳斯达克代码：CRBU - 获取免费报告）首席执行官 Rachel E. Haurwitz 于 3 月 14 日星期五以交易方式购买了 20,000 股该股票。每股平均购买成本为 1.02 美元，总交易额为 20,400.00 美元。交易完成后，首席执行官现在持有公司 3,369,395 股股票，估值约为 3,436,782.90 美元。此交易代表其持股增加了 0.60%。该购买在向美国证券交易委员会（SEC）提交的文件中披露，相关信息可通过 SEC 网站获取。</p>
<p>获取 <strong>Caribou Biosciences</strong> 的提醒：</p>
<h2>Caribou Biosciences 股价上涨 0.5%</h2>
<ul>
<li>MarketBeat 周报 – 7/10 - 7/14</li>
</ul>
<p>周一中午交易时，CRBU 的股价上涨了 0.01 美元，达到了 1.02 美元。该公司的股票交易量为 83,205 股，而其平均交易量为 1,603,439 股。该股票的市值为 9440 万美元，市盈率为-0.62，贝塔值为 2.34。Caribou Biosciences, Inc.的 52 周最低价为 0.98 美元，52 周最高价为 5.77 美元。该公司的 50 日移动平均价格为 1.37 美元，200 日移动平均价格为 1.77 美元。</p>
<p>Caribou Biosciences（纳斯达克代码：CRBU - 获取免费报告）最近于 3 月 10 日星期一公布了季度财报。公司报告该季度每股收益为（0.39 美元），超出分析师一致预期的（0.40 美元）0.01 美元。该季度的收入为 208 万美元，而分析师预期为 211 万美元。Caribou Biosciences 的净利润率为-1,290.81%，股本回报率为-45.46%。研究分析师预计 Caribou Biosciences, Inc.在本年度将发布-1.64 的每股收益。</p>
<h2>机构资金流入和流出</h2>
<ul>
<li>3 只生物科技股票值得长期投资</li>
</ul>
<p>机构投资者最近增加或减少了对该股票的持股。摩根大通在第四季度将其在 Caribou Biosciences 的持股增加了 475.9%。摩根大通现在持有该公司 2,495,922 股股票，价值 396.9 万美元，此前在该期间内又购买了 2,062,563 股。Jacobs Levy Equity Management Inc.在第四季度购买了 Caribou Biosciences 的新股份，价值约为 192.1 万美元。Schonfeld Strategic Advisors LLC 在第四季度将其在 Caribou Biosciences 的持股增加了 28.4%。Schonfeld Strategic Advisors LLC 现在持有该公司 2,113,272 股股票，价值 336 万美元，此前又购买了 467,738 股。Two Sigma Advisers LP 在第四季度将其在 Caribou Biosciences 的持股增加了 39.5%。Two Sigma Advisers LP 现在持有该公司 1,470,700 股股票，价值 233.8 万美元，此前又购买了 416,600 股。最后，Ameriprise Financial Inc.在第四季度购买了 Caribou Biosciences 的新股份，价值约为 649,000 美元。目前 77.51% 的股票由机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位分析师对该股票发表了评论。花旗集团将 Caribou Biosciences 的目标价从 30.00 美元下调至 6.00 美元，并在 11 月 26 日的研究报告中对该股票给予 “买入” 评级。美国银行将 Caribou Biosciences 的目标价从 13.00 美元下调至 11.00 美元，并在 1 月 7 日的研究报告中对该公司给予 “买入” 评级。根据 MarketBeat.com 的数据，五位股票研究分析师对该股票给予了买入评级，Caribou Biosciences 的平均评级为 “买入”，平均目标价为 10.33 美元。</p>
<ul>
<li>辉瑞刚刚在这家生物科技公司投资了 2500 万美元</li>
</ul>
<p><strong>查看我们最新的 CRBU 股票分析</strong></p>
<h2>Caribou Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Caribou Biosciences, Inc.是一家临床阶段的生物制药公司，专注于开发基因编辑的异体细胞疗法，用于治疗美国及国际上的血液恶性肿瘤。其主要产品候选药物是 CB-010，一种异体抗 CD19 CAR-T 细胞疗法，目前正在进行 1 期临床试验，以治疗复发或难治性 B 细胞非霍奇金淋巴瘤。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Caribou Biosciences</li>
<li>最活跃的股票：美元交易量与股数交易量</li>
<li>消费者正在削减开支，但这三只股票将保持强劲</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>迪士尼股票：验证其复苏的四个关键指标</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>抗压投资：三只能够应对市场波动的股票</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Caribou Biosciences 吗？</h2>
<p>在你考虑投资 Caribou Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Caribou Biosciences 并不在名单上。</p>
<p>虽然 Caribou Biosciences 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CRBU

<p>Caribou Biosciences, Inc. 首席执行官 Rachel E. Haurwitz 以每股 1.02 美元的价格购买了 20,000 股，总计 20,400 美元，使她的持股增加至 3,369,395 股，估值约为 344 万美元。此次收购已向美国证券交易委员会（SEC）披露。该公司的股票最近交易价格为 1.02 美元，市值为 9440 万美元。分析师预测当前年度的每股收益（EPS）为 -1.64，机构投资者持有 77.51% 的股份。花旗集团和美国银行已调整其目标价格，平均目标价为 10.33 美元，市场共识评级为 “买入”</p>

<p>Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) CEO Rachel E. Haurwitz acquired 20,000 shares of the stock in a transaction on Friday, March 14th. The stock was bought at an average cost of $1.02 per share, for a total transaction of $20,400.00. Following the transaction, the chief executive officer now owns 3,369,395 shares of the company's stock, valued at approximately $3,436,782.90. This trade represents a 0.60 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>Caribou Biosciences, Inc.（纳斯达克代码：CRBU - 获取免费报告）首席执行官 Rachel E. Haurwitz 于 3 月 14 日星期五以交易方式购买了 20,000 股该股票。每股平均购买成本为 1.02 美元，总交易额为 20,400.00 美元。交易完成后，首席执行官现在持有公司 3,369,395 股股票，估值约为 3,436,782.90 美元。此交易代表其持股增加了 0.60%。该购买在向美国证券交易委员会（SEC）提交的文件中披露，相关信息可通过 SEC 网站获取。</p>
</div><p>Get <strong>Caribou Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Caribou Biosciences</strong> 的提醒：</p>
</div><h2>Caribou Biosciences Trading Up 0.5 %</h2>
<div class="lb-trans"><h2>Caribou Biosciences 股价上涨 0.5%</h2>
</div><ul>
<li>MarketBeat Week in Review – 7/10 - 7/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 7/10 - 7/14</li>
</ul>
</div><p>Shares of CRBU traded up $0.01 during mid-day trading on Monday, reaching $1.02. The company's stock had a trading volume of 83,205 shares, compared to its average volume of 1,603,439. The stock has a market cap of $94.40 million, a PE ratio of -0.62 and a beta of 2.34. Caribou Biosciences, Inc. has a 52 week low of $0.98 and a 52 week high of $5.77. The company's fifty day moving average price is $1.37 and its two-hundred day moving average price is $1.77.</p>
<div class="lb-trans"><p>周一中午交易时，CRBU 的股价上涨了 0.01 美元，达到了 1.02 美元。该公司的股票交易量为 83,205 股，而其平均交易量为 1,603,439 股。该股票的市值为 9440 万美元，市盈率为-0.62，贝塔值为 2.34。Caribou Biosciences, Inc.的 52 周最低价为 0.98 美元，52 周最高价为 5.77 美元。该公司的 50 日移动平均价格为 1.37 美元，200 日移动平均价格为 1.77 美元。</p>
</div><p>Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01. The firm had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. Research analysts anticipate that Caribou Biosciences, Inc. will post -1.64 EPS for the current year.</p>
<div class="lb-trans"><p>Caribou Biosciences（纳斯达克代码：CRBU - 获取免费报告）最近于 3 月 10 日星期一公布了季度财报。公司报告该季度每股收益为（0.39 美元），超出分析师一致预期的（0.40 美元）0.01 美元。该季度的收入为 208 万美元，而分析师预期为 211 万美元。Caribou Biosciences 的净利润率为-1,290.81%，股本回报率为-45.46%。研究分析师预计 Caribou Biosciences, Inc.在本年度将发布-1.64 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>3 Biotech Stocks to Buy for Long-Term Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只生物科技股票值得长期投资</li>
</ul>
</div><p>Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase &amp; Co. grew its position in shares of Caribou Biosciences by 475.9% in the 4th quarter. JPMorgan Chase &amp; Co. now owns 2,495,922 shares of the company's stock worth $3,969,000 after buying an additional 2,062,563 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Caribou Biosciences in the 4th quarter worth about $1,921,000. Schonfeld Strategic Advisors LLC grew its position in shares of Caribou Biosciences by 28.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock worth $3,360,000 after buying an additional 467,738 shares during the period. Two Sigma Advisers LP grew its position in Caribou Biosciences by 39.5% during the 4th quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company's stock valued at $2,338,000 after purchasing an additional 416,600 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in Caribou Biosciences during the 4th quarter valued at about $649,000. 77.51% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该股票的持股。摩根大通在第四季度将其在 Caribou Biosciences 的持股增加了 475.9%。摩根大通现在持有该公司 2,495,922 股股票，价值 396.9 万美元，此前在该期间内又购买了 2,062,563 股。Jacobs Levy Equity Management Inc.在第四季度购买了 Caribou Biosciences 的新股份，价值约为 192.1 万美元。Schonfeld Strategic Advisors LLC 在第四季度将其在 Caribou Biosciences 的持股增加了 28.4%。Schonfeld Strategic Advisors LLC 现在持有该公司 2,113,272 股股票，价值 336 万美元，此前又购买了 467,738 股。Two Sigma Advisers LP 在第四季度将其在 Caribou Biosciences 的持股增加了 39.5%。Two Sigma Advisers LP 现在持有该公司 1,470,700 股股票，价值 233.8 万美元，此前又购买了 416,600 股。最后，Ameriprise Financial Inc.在第四季度购买了 Caribou Biosciences 的新股份，价值约为 649,000 美元。目前 77.51% 的股票由机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several analysts have commented on the stock. Citigroup lowered their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, November 26th. Bank of America reduced their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Caribou Biosciences has an average rating of &#34;Buy&#34; and an average target price of $10.33.</p>
<div class="lb-trans"><p>几位分析师对该股票发表了评论。花旗集团将 Caribou Biosciences 的目标价从 30.00 美元下调至 6.00 美元，并在 11 月 26 日的研究报告中对该股票给予 “买入” 评级。美国银行将 Caribou Biosciences 的目标价从 13.00 美元下调至 11.00 美元，并在 1 月 7 日的研究报告中对该公司给予 “买入” 评级。根据 MarketBeat.com 的数据，五位股票研究分析师对该股票给予了买入评级，Caribou Biosciences 的平均评级为 “买入”，平均目标价为 10.33 美元。</p>
</div><ul>
<li>Pfizer Just Invested $25 million In This Biotech</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞刚刚在这家生物科技公司投资了 2500 万美元</li>
</ul>
</div><p><strong>View Our Latest Stock Analysis on CRBU</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 CRBU 股票分析</strong></p>
</div><h2>Caribou Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Caribou Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.</p>
<div class="lb-trans"><p>Caribou Biosciences, Inc.是一家临床阶段的生物制药公司，专注于开发基因编辑的异体细胞疗法，用于治疗美国及国际上的血液恶性肿瘤。其主要产品候选药物是 CB-010，一种异体抗 CD19 CAR-T 细胞疗法，目前正在进行 1 期临床试验，以治疗复发或难治性 B 细胞非霍奇金淋巴瘤。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Caribou Biosciences</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Consumers Are Cutting Back, But These 3 Stocks Will Stay Strong</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Disney Stock: 4 Key Metrics Validating Its Comeback</li>
<li>Canadian Penny Stocks: Can They Make You Rich?</li>
<li>Resilient Investing: 3 Stocks Built to Weather Market Volatility</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Caribou Biosciences</li>
<li>最活跃的股票：美元交易量与股数交易量</li>
<li>消费者正在削减开支，但这三只股票将保持强劲</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>迪士尼股票：验证其复苏的四个关键指标</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>抗压投资：三只能够应对市场波动的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Caribou Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Caribou Biosciences 吗？</h2>
</div><p>Before you consider Caribou Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Caribou Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Caribou Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Caribou Biosciences 并不在名单上。</p>
</div><p>While Caribou Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Caribou Biosciences 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Caribou Biosciences, Inc.（纳斯达克股票代码：CRBU）首席执行官 Rachel E. Haurwitz 收购了 20,000 股公司股票